Adicet Bio FY2026 Earnings Forecast Boosted by HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET) – HC Wainwright raised their FY2026 EPS estimates for Adicet Bio in a report issued on Friday, November 6th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($7.62) for the year, up from their prior estimate of ($8.05). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Adicet Bio’s current full-year earnings is ($6.76) per share. HC Wainwright also issued estimates for Adicet Bio’s Q4 2026 earnings at ($1.99) EPS, Q1 2027 earnings at ($2.10) EPS, Q2 2027 earnings at ($1.88) EPS, Q3 2027 earnings at ($1.71) EPS, Q4 2027 earnings at ($1.77) EPS and FY2027 earnings at ($7.39) EPS.

Adicet Bio (NASDAQ:ACET) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.20).

A number of other brokerages have also recently commented on ACET. Guggenheim restated a “buy” rating and issued a $90.00 price target (down from $100.00) on shares of Adicet Bio in a research report on Thursday, August 6th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price (up from $25.00) on shares of Adicet Bio in a research report on Monday, September 28th. Wall Street Zen downgraded Adicet Bio from a “hold” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adicet Bio in a report on Friday, August 21st. Finally, Benchmark reissued a “buy” rating on shares of Adicet Bio in a report on Tuesday, September 29th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.80.

Adicet Bio Stock Performance

Shares of NASDAQ:ACET opened at $2.99 on Tuesday. The firm has a market cap of $27.99 million, a PE ratio of -0.35 and a beta of 1.69. Adicet Bio has a 12-month low of $2.87 and a 12-month high of $11.20. The company has a quick ratio of 6.71, a current ratio of 6.71 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $6.43 and its two-hundred day moving average price is $7.54.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ACET. Regeneron Pharmaceuticals Inc. bought a new position in shares of Adicet Bio in the 2nd quarter valued at $522,819. Rangeley Capital LLC grew its position in Adicet Bio by 124.0% during the 1st quarter. Rangeley Capital LLC now owns 56,000 shares of the company’s stock worth $381,000 after acquiring an additional 30,999 shares during the last quarter. Johnson & Johnson bought a new stake in Adicet Bio during the 2nd quarter worth $196,811. Squarepoint Ops LLC bought a new stake in Adicet Bio during the 2nd quarter worth $132,000. Finally, AXQ Capital LP acquired a new position in Adicet Bio in the 2nd quarter worth about $95,000. 83.89% of the stock is currently owned by institutional investors and hedge funds.

Adicet Bio Company Profile

Adicet Bio, Inc is a clinical-stage biotechnology company developing allogeneic T-cell therapies for the treatment of cancer. The company’s platform is focused on genetically engineered gamma delta T cells, an immune-cell type that can recognize and attack abnormal cells while potentially offering advantages for off-the-shelf cell therapy development.

Adicet’s product candidates are designed to incorporate chimeric antigen receptors and other modifications intended to improve tumor targeting, persistence, and activity.